Neal Bhatia, MD, provides an overview of atopic dermatitis (AD) and the diagnostic process, as well as how its severity impacts the patient.
Improving Access to Appropriate Therapies in Atopic Dermatitis
Dr Neal Bhatia explains the available treatment options for patients with AD, including their relation to guideline recommendations.
A dermatology expert highlights the role JAK inhibitors play in AD therapy, from mechanism of action to ruxolitinib and the TrUE AD1 and -2 trials.
Dr Bhatia concludes our discussion by outlining what factors physicians should be cognizant of when prescribing therapies to patients with AD.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
FDA tentatively approves first generic lenacapavir for HIV prevention in lower-income countries
2
New pulmonary fibrosis drugs put guidelines in focus, Prusi says | AMCP Nexus 2026
3
Fewer than half of newly diagnosed children with type 1 diabetes get autoantibody testing
4
Targeted therapies for atopic dermatitis reduce hospitalizations and ER visits, but cost is a different story
5